粪便微生物群移植治疗多重合并症患者的复发性感染：来自三级医疗社区医院的长期安全性和有效性结果
Fecal Microbiota Transplantation for Recurrent Infection in Patients With Multiple Comorbidities: Long-Term Safety and Efficacy Results From a Tertiary Care Community Hospital.
作者信息
Raghu Subramanian Charumathi, Talluri Swapna, Khan Safi Ullah, Katz Jeffry A, Georgetson Michael, Sinh Preetika
机构信息
Department of Medicine, Guthrie Clinic/Robert Packer Hospital, Sayre, PA, USA.
Washington Hospital Healthcare System, Fremont, CA, USA.
出版信息
Gastroenterology Res. 2020 Aug;13(4):138-145. doi: 10.14740/gr1275. Epub 2020 Aug 14.
BACKGROUND
Cure rates of infection (CDI) with fecal microbiota transplant (FMT) have been promising. However, there is debate regarding success of FMT in patients with comorbidities.
METHODS
Electronic chart review was done to collect data on patients who underwent FMT from January 2015 to August 2017. Charts were analyzed in November 2018 with a median follow-up of 25.4 months (interquartile range 20 - 31 months).
RESULTS
Twenty patients underwent FMT. The primary success rate at our institution was 90% and overall success rate was 100%. Six patients (43%) had FMT failure (two early and four late).
CONCLUSIONS
This case series is a description of our center's initial experience with FMT for treatment of recurrent CDI. Our high success rate reiterates the efficacy and safety of FMT in this population including patients with comorbidities.
背景
粪便微生物群移植（FMT）治疗艰难梭菌感染（CDI）的治愈率很可观。然而，对于合并症患者FMT的成功率存在争议。
方法
进行电子病历回顾，以收集2015年1月至2017年8月接受FMT患者的数据。2018年11月分析病历，中位随访时间为25.4个月（四分位间距20 - 31个月）。
结果
20例患者接受了FMT。我们机构的主要成功率为90%，总体成功率为100%。6例患者（43%）FMT失败（2例早期失败和4例晚期失败）。
结论
本病例系列描述了我们中心用FMT治疗复发性CDI的初步经验。我们的高成功率重申了FMT在包括合并症患者在内的这一人群中的有效性和安全性。
Zotero 插件